Drugs available for radioisotope labeling include: small molecules, peptides, proteins, polysaccharides, enzymes, antibodies, ADCs, stem cells, exosomes, etc.

Tissue distribution and material balance studies of 125I-labeled compounds

-ADME studies of ³H/¹⁴C labeled compounds
-³H/¹⁴C-labeled compounds rodent/non-rodent pharmacokinetic studies
-³H/¹⁴C-labeled compounds rodent ex vivo tissue distribution study (liquid scintillation counting method)
-³H/¹⁴C-labeled compounds rodent QWBA tissue distribution study
-Biliary excretion study of ³H/¹⁴C-labeled compounds in rat BDC model
-³H/¹⁴C-labeled compounds rodent and non-rodent material balance study
-Biotransformation (metabolite profiling) and metabolite identification of ³H/¹⁴C-labeled compounds in animals.
-Olinda in vivo dose estimation.

PET/SPECT imaging studies
-Radioisotope labeling of ⁸⁹Zr, ⁶⁸Ga, ⁶⁴Cu, etc.
-PET/SPECT in vivo imaging studies of small and large animals

Clinical studies of radioisotope labeled compounds ⁽¹⁴C)
-Radioactive drug delivery formulation, stability and purity testing
-Prototype drug and major metabolite analysis (LC-MS/MS)
-Human whole blood/plasma total radioactivity detection (liquid flash detection)
-Human material balance studies
-Biotransformation (metabolite profiling) and metabolite characterization of drugs in the human body